The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.
About Covishield:
The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.
About Covaxin:
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Important takeaways for all competitive exams:
The Securities and Exchange Board of India (SEBI) has operationalized the Past Risk and Return…
Have you wondered if there are places on Earth where it never snows? Yes, such…
The Employees Provident Fund Organization is set to launch the new digital platform called the…
The Reserve Bank of India had introduced the revised guidelines for loan restructuring for the…
The India and Sri Lanka successfully conducted the fourth edition of the bilateral diving exercise…
Today, digital payments have become a daily habit in India. From buying vegetables to paying…